Introduction
Rapid initiation of antiretroviral therapy (ART) -as early as the day of HIV diagnosis -may be important in global HIV management for two main reasons. First, as a means to control the HIV epidemic, in the absence of a vaccine or cure: undetectable virus means untransmissible virus (U = U) [1, 2] . Secondly, to optimize the health of people living with HIV (PLWH) [3] .
Rapid-start ART has been adopted by several programmes in low-and middle-income countries (LMICs) [4] [5] [6] [7] [8] , and some in high-income countries (HICs) [9] [10] [11] [12] . Robust evidence demonstrates the benefits of rapid-start strategies, especially in LMIC settings with high prevalence of HIV infection, late presentation and limited access to care [3] [4] [5] [6] [7] [8] 13 ]. However, good-quality evidence is lacking regarding the optimum timing, format and relative value of rapid initiation interventions in HICs.
Although there exist strong arguments in favour of rapidstart ART, there are also reasonable grounds to individualize treatment initiation to suit the patient's overall health and social needs. In HIC settings in which personalised health care is advocated, the optimal timing of ART initiation warrants further evaluation. This article considers the issues around rapid-start ART, with a focus on HICs (where evidence is weak), and identifies key knowledge gaps that, if addressed, might help us understand whether same-day ART should be the global standard for HIV management. Importantly, the article focuses on ART initiation in people who do not present with concomitant, serious, opportunistic infections (OI) or cancers. The clinical management of these complex cases is outside the scope of the present manuscript.
There is no clear, unified, evidence-based definition for rapid-start ART; initiation is considered "rapid" when treatment begins as soon as possible after confirming HIV infection [9, 14, 16] . Although the World Health Organization (WHO) recommends immediate ART for all PLWH [17] , only the WHO Guidelines for Managing Advanced HIV specify that initiation should be within 7 days of diagnosis, ideally on the same day [16, 17] . This timeframe may not have been adopted by countries universally for various reasons. As WHO guidelines are most influential in LMICs, any goals they set should be widely attainable; given the complexities of healthcare delivery in LMICs, initiation within 7 days seems a realistic timeframe.
In addition, little evidence supports a particular day for initiation because a specific start day has rarely been the focus of research [8, 9, 14] . For example, the protocol for START stipulated that the immediate-initiation group commenced ART after having two CD4 counts of > 500 cells per mm 3 ≥ 2 weeks apart in the 60 days before enrolment [18] . Consequently, in START, no study participant received same day ART, although 98% of those in the immediate-start arm commenced ART within 2 months [18] . Following START [18] , the principle of expedited ART initiation has become widely acknowledged: international organizations consistently state that it is unacceptable to delay ART or base treatment decisions on CD4 cell thresholds [19] [20] [21] [22] . The question now focuses on how soon to initiate ART. Although no guidance recommends a specific starting day [19] [20] [21] [23] [24] [25] , several publications call for more investigation of same-day ART [8, 9, 13, 18, 26] : guidelines from the International Antiviral Society-USA now explicitly state that ART should commence immediately after diagnosis [21] .
"Same-day" ART truly means within 24 h of diagnosis in centres where clinicians work to standard protocols and have access to very few baseline tests, as is frequently the case in LMICs [8] . Elsewhere, particularly in HICs, "immediate" may mean 5, 7 or even 14 days postdiagnosis, to suit individual circumstances or local protocols for diagnostic workup [18] . But even in HICs, some clinicians initiate ART before all baseline test results (including HLA-B*5701, genotypic antiretroviral resistance testing [GART] and organ function (renal, hepatic and haematopoietic tissue) are available [9] .
Rapid ART in LMICs
In LMICs, rapid-start ART is evidence-based, driven by high rates of late-stage HIV presentation and loss to follow up, which negatively affect morbidity and mortality [4] [5] [6] [7] [8] . Rapid-start ART was evaluated in four high-quality randomized trials: RapIT (South Africa; ≤ 90 days of HIV diagnosis, Ref. [8] ), START-ART (Uganda; ≤ 14 days of diagnosis, ref. [4] ), and same-day ART in Haiti [13] and Lesotho (CASCADE) [7] . These programmes have resulted in improved rates of viral suppression [7, 8, 13 ] and retention in care [7, 13] .
Rapid-start ART was evaluated in a systematic review involving eight observational studies and five qualitative studies (12 LMICs and two HICs); findings favored sameday initiation, compared with standard care (Fig. 1) [3] . Briefly, study populations included pregnant and nonpregnant adults, and people with acute HIV infection; ART was initiated between day of diagnosis and 14 days' post-diagnosis, depending on the protocol [3] .
In LMICs, benefits of rapid-start ART vs. standard care include higher rates of linkage to care at 3 (68.6% vs. 43.1%) and 12 months (56% vs. 43%; P = 0.03) [7] ; shorter (by 3 months) time to viral suppression [9] ; substantial (26%) increase in the absolute number of people achieving viral suppression [8] ; higher rates of HIV suppression at 12 months (50.4% vs 34.3%) [7] ; 36% increase in ART uptake [8] ; and significantly better outcomes [7] , including rates of severe illness [6] , adverse events or death [18] . Fig. 1 Outcomes from randomized trials that compare same-day ART initiation vs. standard of care [4, 7, 8, 13] . Reproduced with permission [3] . ART, antiretroviral therapy; CI, confidence interval; LTFU, long-term follow-up.
Rapid ART may also reduce the rate of onward HIV transmission, as demonstrated in research involving serodiscordant couples from nine countries (eight of which were LMICs) [5] .
In LMICs, rapid-start ART is working towards the UNAIDS 90-90-90 goal [7, 15] , although there are some signs that rapid-start ART may not meet targets for longterm viral suppression [3, 27, 28] . This may be a consequence of restricted access to viral load monitoring, relatively inefficient ART regimens, poor linkage to/retention in care and limited care provision rather than the speed of ART initiation per se [7, 27, [29] [30] [31] . Challenges remain in ongoing provision of ART in LMICs that are beyond the scope of this article [15, 32] .
Rapid ART in HICs
In HICs, evidence for rapid-start ART comes from relatively small-scale studies or cohorts within global trials [9] [10] [11] [12] 33] . However, the concept of early ART originated in a predominantly US-based study involving 45 clinics, published in 2009 [34] . In this study, commencing physician's choice of ART within 2 weeks of starting OI therapy reduced disease progression and death rates: AIDS progression occurred in 34 subjects in whom ART was deferred until OI therapy completion, but only 20 subjects who received ART within 2 weeks of starting OI therapy (OR = 0.51; 95% CI: 0.27-0.94; P = 0.035) [34] . Additionally, time to AIDS progression or death was significantly slower in the early ART arm (HR = 0.53; 95% CI: 0.30-0.92; P = 0.02) [34] .
Differences in HIV presentation, management and health systems make it difficult to extrapolate high-quality evidence for rapid ART from LMIC to HIC settings. Typically in HICs, HIV is diagnosed earlier in the disease process and PLWH present with relatively high CD4 counts [32] . In addition, loss to follow up is not of primary concern in HICs, where the infrastructure facilitates many ways to reach those who disengage from care. It is important to acknowledge, however, that loss to follow up is an issue within some disenfranchised HIC communities, and that same-day ART may add considerable value in these situations [9] .
Given the lack of robust evidence, there is no standard framework for rapid-start ART in HIC settings. However, commitment to this approach has strengthened in the 2018 International Antiviral Society-USA guidelines [21,] which note that same-day ART has been successful in some urban settings to facilitate adequate uptake, provided that all aspects of conventional care (e.g. access to testing and other resources) are included. [21] . The National Institutes of Health (USA) simply describes same-day ART as an investigational approach that remains unproven [19] . Such caution from both organizations may be an artefact of US healthcare delivery, which requires co-ordination of multiple stakeholders, including insurance providers, before treatment begins. Consequently, there are inherent complexities in providing immediate test-and-treat in the USA, especially as diagnosing asymptomatic HIV is not considered a clinical or public health emergency.
Both the European AIDS Clinical Society (EACS) and the British HIV Association (BHIVA) acknowledge that accumulating evidence favors same-day ART initiation, but advise that PLWH should not feel pressured to begin treatment immediately [20, 22] .
There are no specific guidelines on immediate ART initiation in Australia or New Zealand [35] , and although there is much progress in HIV care provision in South and Central America, rapid-start (especially same-day) programmes are yet to gain traction [27] .
Clinical evidence
Evidence favors urgent ART initiation in pregnant women with HIV and PLWH presenting with most OIs, CD4 counts < 200 cells/mL, an AIDS-defining condition, or hepatitis B or C co-infection [19] . Beyond these situations, in PLWH who do not have serious OI or cancers, rapid-start ART may reduce the time to achieve virologic suppression [3] and risk of HIV-associated complications [10] or death [3] . Rapid-start ART may also reduce the rate of onward transmission [11, 36] : no cases of phylogenetically related transmission were observed among serodiscordant MSM couples having condomless anal intercourse, if the infected partner had virologic suppression [2, 36] .
Rapid ART initiation, along with pre-exposure prophylaxis in high-risk people, has contributed to a dramatic reduction in HIV-incidence in some communities [12, 37] . For example, in 2016, only 233 people were newly diagnosed with HIV in San Francisco, compared with 523 people in 2008 [37] . Rapid-start ART may also have immunological benefits by improving surrogate disease markers (e.g. enhanced recovery of CD4 cell counts and CD4/CD8 ratio) [38, 39] .
In LMICs, ART initiation must be delayed in people with intracranial OI and raised intracranial pressure [40] . However, such guidance is not mandatory in HICs, where neurological conditions and their sequelae can be aggressively managed; ART should be initiated within 2 weeks of diagnosis in these settings [21] , with the proviso that such situations are complex and beyond the scope of the present article.
Same-day ART may also help to empower PLWH; enabling them to proactively take control of their infection, for their own health and for the benefit of others (e.g. to reduce transmission risk) [11, 26] . A Cochrane review is assessing the effects of rapid start ART on treatment outcomes and mortality; its findings should be instructive [14] .
No reason to delay
No clinician should continue to operate on a "wait 2-3 months" or CD4 threshold-driven strategy for initiating ART, even in people with asymptomatic HIV. Delaying ART negatively affects the health and wellbeing of all PLWH, regardless of their CD4 count [18] . Despite a long tradition of believing that patient preparedness is critical to achieving ART adherence, this assumption is not evidence based. Ford et al. [3] observed a trend towards loss to follow up at 6 months in his meta-analysis of those who rapidly initiated ART, but this finding was not statistically significant (RR 1.85, 95% CI 0.96-3.55).
Although the very long-term impact and adverse-effect burden of ART is unknown, there is no evidence that unfavorable outcomes are more likely with rapid-start than with delayed initiation. Evidence suggests that virologic outcomes are little different regardless of whether ART initiation follows a public-health or individualized approach [41] . The present issue is, however, not to discuss the relative merits of same-day vs. 1-or 2-week initiation or individualization vs. standardization, although these are key knowledge gaps that warrant further research. Instead, the most pressing need is to cease the practice of waiting months to years before initiating ART in people with asymptomatic HIV infection.
Real-world practices in HICs
The 2018 EACS Guidelines state that initial ART regimens for treatment-na€ ıve PLWH should be individualized and be based on two NRTIs plus an INSTI as the preferred third agent [22] . The US Department of Health and Human Services Guidelines also recommend similar triple regimens and advocate rapid ART initiation, if this suits the individual's circumstances [19] . Both guidelines also acknowledge the emerging data that support two-drug regimens when three-drug regimens are not optimal [19, 22] .
Despite the lack of strong evidence, rapid-start (including same-day) ART at HIV diagnosis is already practiced by some clinicians in HICs who believe that HIV requires urgent medical attention to maintain the health of the individual, fully suppress virologic replication and reduce the risk of onward transmission.
In Australia, the New South Wales Health Department aspires to start all PLWH on ART within 6 weeks of diagnosis by 2020. However, there are no formal guidelines for ART administration in Australia. Urban clinics have no unified protocol for rapid-start ART; few urban clinics (outside hospitals) offer a dispensing service, therefore even where same-day start is practiced, the first dose is not taken within clinic. Consequently, despite being handed a prescription PLWH may not necessarily commence ART immediately. However, recent data from specialist HIV services in Victoria show that offering testand-treat care to men who have sex with men has led to a rapid decline in the time between HIV diagnosis and viral suppression, and a steep reduction in HIV incidence in this community since 2012 [12] .
In the UK, Chelsea and Westminster Hospital HIV Department actively recommends ART initiation at diagnosis, to help reduce the risk of onward HIV transmission [11] and foster immediate patient engagement. As with the Australian protocol, the first dose is not administered in an observed setting. Spanish guidelines recommend that ART initiation is personalized, to suit lifestyle, comorbidities, possible interactions, and risk of poor adherence [24] . Italian guidelines recommend ART in all PLWH, independent of CD4 count [23] . Immediate-start ART (without waiting for HLA-B*5701 and GART results) is recommended for people with acute HIV infection, with the aim of reducing the latent viral reservoir [23] .
RAPID strategies
The most widely known immediate ART program is RAPID [9] . In this streamlined model, PLWH receive a multi-service intervention on the day of HIV testing ( Fig. 2) [9] . ART is initiated within 72 h of diagnosis (usually same day), and the first dose is taken in an observed setting [9] . People receive 5 days' therapy, then transfer to their health insurance coverage. RAPID is now the standard program for ART initiation across San Francisco (www.gettingtozerosf.org/rapid-committee/).
It is important to acknowledge that evidence for RAPID comes from a pilot study involving 86 PLWH [9] . In this proof-of-concept study, compared with a historical standard-care cohort, RAPID shortened the time from referral to viral suppression by 3 months (Fig. 3) [9] . RAPID was well accepted by PLWH: 37/39 (94.9% of subjects) started ART within 24 h of diagnosis, although during the 18-month initial study period (n = 86) loss to follow-up was similar in the RAPID (10.3%) and standard-care groups (14.9%) [9] .
In addition to the dramatic reduction in new diagnoses of HIV infection across San Francisco [37] , between 2013 and 2016 RAPID further improved the time between diagnosis, ART initiation and viral suppression [42] . Across San Francisco, RAPID decreased the medium time from diagnosis to viral suppression by 54% (from 134 to 61 days), the time from first care to ART initiation by 96% (from 27 to 1 day) [42] . By 2016, the time from diagnosis to care was lowest for youths, Latin Americans and Asians/Pacific Islanders (same-day), and highest among African Americans and homeless people (6 days) [42] . RAPID also decreased the percentage of time spent above viremic thresholds in the 12 months following HIV diagnosis (from 70% at > 200 copies/mL in 2008 to 32% in 2016, ref. [37] ).
Undoubtedly RAPID is an intriguing approach to ART initiation, but its principles should be locally adjusted and tested in substantially larger cohorts (in different healthcare settings) before it can be fully considered for national or international recommendations on starting ART. It will be interesting to observe how transferable RAPID proves to be, within and beyond the US healthcare system. Elsewhere, RAPID has received acclaim [19, 26, 43] , with encouraging preliminary data on referral to long-term care and short-term virologic suppression in the high-middle income setting of Bangkok, Thailand [43] . Researchers should be encouraged to obtain additional evidence, to establish the impact of RAPID on Fig. 2 Standard care based on universal ART guidelines (upper panels) vs. RAPID program same-day ART initiation (lower panels), in people newly diagnosed with HIV infection. In RAPID, the first encounter between the person and their HIV care giver provides comprehensive ART management, often on the day of diagnosis. In standard care, ART is only initiated after three encounters. Reproduced with permission [9] . linkage to care, viral load, transmission and long-term outcomes [9, 14, 19, 26, 43] . RAPID may require substantial testing and adaptation before being more widely applied but is not necessarily more resource-intensive than standard initiatives [6, 9, 18] . The same care is provided, whether in one day or across several days, but the intensive approach reduces barriers that people encounter before receiving a prescription (e.g. blood drawing, laboratory testing, chasing results, contacting tested people, communicating results and counseling and deciding on the specific ART for initiation).
In principle, same-day ART may be very appropriate in socially disadvantaged settings, where rates of loss to follow up and poor linkage to care are high. HIV prevalence rates in areas of urban poverty in the USA are 2.1%, similar to rates observed in some LMICs in sub-Saharan Africa [44] .
Red herrings of ART initiation: adherence and resistance
Poor adherence is a primary cause of ART failure and resistance selection [45] but is no reason to delay ART, particularly in HICs, where once-daily therapies that offer a low pill burden make optimal adherence achievable and provide high levels of virologic suppression [33, 46] . It is important to acknowledge that adherence may be poor in HICs among people on low incomes, who may be unable to fund the pharmacy co-payment [47] . Aside from this, in HICs, if the individual's literacy level, concomitant physical, mental and social-care issues, and history of substance abuse are evaluated at diagnosis, the risk of poor adherence can be identified and managed, but research is needed to establish how to best identify those at risk of poor adherence and optimal interventions.
Resistance testing should always be undertaken at HIV diagnosis, but in HICs it is reasonable to start ART before baseline results are available because of the low risk of InSTI resistance or multiple resistance mutations to NRTIs [46, 48] . In this context, first-line ART regimens must include a drug with a high genetic barrier to resistance [22] . Boosted PIs or second-generation InSTIs (e.g. dolutegravir, bictegravir) are preferred because of the heightened risk of virologic failure with NNRTI-containing ART regimens [22] . In all cases, it is important to follow up promptly with PLWH À to consider altering the ART regimen À if any laboratory findings give cause for concern.
Second-generation InSTIs are considered almost equivalent to boosted PIs in terms of their barrier to resistance [49, 50] , particularly if GART indicates no baseline NRTI resistance. Transmitted InSTI resistance is uncommon, and triple-drug regimen failure is unlikely within 4 weeks of initiation if there is no InSTI resistance and no NRTI mutations [51, 52] . Consequently, InSTIs are included in the majority of recommended ART initiation regimens [20] [21] [22] [23] [24] . Even in the presence of NRTI resistance, dolutegravir plus two NRTIs retained efficacy in a highly experienced ART cohort [53] . InSTI-containing regimens appear to be better tolerated than most PI-containing regimens, and an InSTI may therefore be the preferred third agent [54] [55] [56] .
The GEMINI 48-week results indicated non-inferior virologic efficacy between a two-drug regimen (dolutegravir and lamivudine) and dolutegravir plus TDF and emtricitabine, in ART-na€ ıve adults with a baseline viral load < 500 000 copies/mL [57] . No treatment-emergent INSTI or NRTI mutations were observed in subjects who met confirmed virologic failure criteria [57] . Whether lower exposure to ART at initiation results in lower levels of long-term drug toxicity is unknown.
Rapid ART and acute HIV infection
Rapid-start ART may have specific benefits in acute (primary) HIV infection, although it remains difficult to obtain high-quality evidence [58] . Acute infection may confer greater risk of onward HIV transmission than chronic infection [59, 60] ; consequently, rapid-start ART could reduce both viral load in the individual and community viral load, through its impact on onward transmission [3, 39] . Early ART initiation may also benefit those with symptomatic primary HIV by arresting a rapid decline in CD4 cells, compared with the decline seen in people with asymptomatic infection [39, 61, 62] .
Additionally, in primary HIV infection, initiating ART may attenuate inflammation and reduce immune activation, particularly in those with/at risk of comorbidities, or older people, compared with initiating ART when infection is chronic but CD4 counts remain high [63] . AIDSrelated mortality is lowest in populations with good, early, HIV control [63] .
Meeting the needs of PLWH
Many international guidelines recommend rapid ART, even if they do not commit to immediate initiation, but whether a one-size-fits-all option is appropriate in realworld settings remains unclear. Studies should explore patient-reported outcomes relating to rapid-start ART, consider whether this approach is universally effective or suitable for specific groups, and identify barriers to access, linkage and retention in care. Patient-reported outcomes might also identify whether rapid-start ART facilitates individual empowerment and care engagement (i.e. to take control of infection and quickly reach undetectable viral levels), or whether the "patient preparedness" model is more appropriate.
To realize the potential benefits of rapid-start ART, new models of care may be required in which HIV diagnosis and management is fully integrated, yet individualized, offering services such as an in-clinic pharmacy, accessible counseling and social support. To achieve this, an infrastructure that extends to telephone, online and app-based platforms, and electronic health records, might be beneficial.
Conclusions
Rapid-start ART -including same-day start À could offer short-and long-term benefits for PLWH and public health globally. No detrimental effects of rapid-start ART have emerged in large studies in LMICs, or in small-scale studies in HICs. However, guidelines need broad evidence in order to make firm recommendations, and more highquality evidence relating to rapid-start ART is required, especially in HICs. It is important to establish the ideal starting point for ART and develop appropriate, evidencebased, protocols. Key knowledge gaps include the impact of rapid-start ART on time to viral suppression, onward HIV transmission and community viral load, emergence of drug resistance, risk of progression to AIDS and adherence/linkage to care. HRQoL data on rapid-start ART are also required, to evaluate the effect of immediate initiation on HIV burden and PLWH empowerment. Data relating to the impact of rapid-start ART on HIV control, therapy costs and clinic productivity will also be important.
Attrition in service provision in the time between HIV diagnosis and starting ART could undermine the UNAIDS 90-90-90 goal [15] . If immediate ART initiation enables PLWH to remain in better overall health for longer and incur lower healthcare-related costs, compared with later initiation, there might be global acceptance of this approach as standard of care. There is an overall unmet need to strengthen collaboration regarding appropriate ART initiation among PLWH, health professionals and research communities. Together we can fill many knowledge gaps and develop evidence-based initiatives that enable all PLWH to receive optimal care from the moment of diagnosis.
